With Rare Exceptions, Plans Stick With Generics for Epilepsy With Chart: Current Market Access to Epilepsy Medications

Pharmaceutical treatment for different types of epilepsy generally still relies on tried-and-true generics, despite recent efforts by drug manufacturers to introduce new branded medications into the mix, PBM insiders say.

Xcopri (cenobamate tablets) launched in May for the treatment of partial-onset seizures in adults. According to manufacturer SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., clinical trials have shown “significant reductions in seizure frequency compared to placebo at all doses studied, and as many as one in five patients achieved zero seizures during the maintenance phase.”

© 2023 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

businessman-viewing-news-update-journalism-headline-on-a-laptop
November 22

News Briefs: CDC Makes More RSV Immunizations Available to Infants

READ MORE
dna-strand
November 22

Papers Delve Into Payment Options for Gene Therapies

READ MORE
pills
November 22

A Closer Look at the Medicare Part D Landscape

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today